SPL7013 Gel (VivaGel®) Retains Potent HIV-1 and HSV-2 Inhibitory Activity following Vaginal Administration in Humans
Figure 2
Recovery of SPL7013 using the SoftCup.
Mass of SPL7013 (mg) recovered in CVF samples from each subject taken at baseline (within 2–10 minutes post-dose) (0), 1, 3, 12 and 24 h post-dose (A). Average recovery of SPL7013 as a percentage dose of SPL7013 administered (105 mg) (B). Error bars denote standard error of the mean.